WO2020259668A1 - 三并环类化合物及其制备方法和用途 - Google Patents
三并环类化合物及其制备方法和用途 Download PDFInfo
- Publication number
- WO2020259668A1 WO2020259668A1 PCT/CN2020/098412 CN2020098412W WO2020259668A1 WO 2020259668 A1 WO2020259668 A1 WO 2020259668A1 CN 2020098412 W CN2020098412 W CN 2020098412W WO 2020259668 A1 WO2020259668 A1 WO 2020259668A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- int
- synthesis
- alkyl
- reaction
- Prior art date
Links
- 0 CC(*=C(*1C2=O)/C3=C/C=C(\C)/C=C/C=C3/C1I)=C2O Chemical compound CC(*=C(*1C2=O)/C3=C/C=C(\C)/C=C/C=C3/C1I)=C2O 0.000 description 16
- XMGLWBNFFHZLNL-HBIPHATFSA-N C[C@@H](CC1=CC(c(cc(cc2)Cl)c2-[n]2nnc(Cl)c2)=C2)[C@@H](c3ncc(-c(cc4CC5)ccc4NC5=O)[nH]3)N1C2=O Chemical compound C[C@@H](CC1=CC(c(cc(cc2)Cl)c2-[n]2nnc(Cl)c2)=C2)[C@@H](c3ncc(-c(cc4CC5)ccc4NC5=O)[nH]3)N1C2=O XMGLWBNFFHZLNL-HBIPHATFSA-N 0.000 description 2
- STVHMYNPQCLUNJ-UHFFFAOYSA-N Brc1ccc2[nH]ncc2c1 Chemical compound Brc1ccc2[nH]ncc2c1 STVHMYNPQCLUNJ-UHFFFAOYSA-N 0.000 description 1
- JKUSLHWSONVTEF-YTEVENLXSA-N C=C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3nc(Cl)c(-c4ccc(N)nc4F)[nH]3)N1C2=O Chemical compound C=C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3nc(Cl)c(-c4ccc(N)nc4F)[nH]3)N1C2=O JKUSLHWSONVTEF-YTEVENLXSA-N 0.000 description 1
- VSFKFVVEUQHAIR-SXBQZSJRSA-N C=C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3ncc(-c(nc4OC5)ccc4NC5=O)[nH]3)N1C2=O Chemical compound C=C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3ncc(-c(nc4OC5)ccc4NC5=O)[nH]3)N1C2=O VSFKFVVEUQHAIR-SXBQZSJRSA-N 0.000 description 1
- CAQGDWLRIQCXSP-UHFFFAOYSA-N CC(C)(C)OC([n]1ncc2cc(Br)ccc12)=O Chemical compound CC(C)(C)OC([n]1ncc2cc(Br)ccc12)=O CAQGDWLRIQCXSP-UHFFFAOYSA-N 0.000 description 1
- OZIVMDWHYAMNDA-UHFFFAOYSA-N CC(C)(C)OC([n]1ncc2cc(C(CBr)=O)ccc12)=O Chemical compound CC(C)(C)OC([n]1ncc2cc(C(CBr)=O)ccc12)=O OZIVMDWHYAMNDA-UHFFFAOYSA-N 0.000 description 1
- JKIOPRZLYCCRRX-UHFFFAOYSA-N CCOC(C1(CC1)Oc(cc(cc1)Br)c1[N+]([O-])=O)=O Chemical compound CCOC(C1(CC1)Oc(cc(cc1)Br)c1[N+]([O-])=O)=O JKIOPRZLYCCRRX-UHFFFAOYSA-N 0.000 description 1
- MDJIHPAJODDQOO-UHFFFAOYSA-N CCOC(c(cc1N=C2)ccc1NC2=O)=C Chemical compound CCOC(c(cc1N=C2)ccc1NC2=O)=C MDJIHPAJODDQOO-UHFFFAOYSA-N 0.000 description 1
- SRXYBKDQJWUXMA-UHFFFAOYSA-N CCOC(c(cc1OC23CC2)ccc1NC3=O)=C Chemical compound CCOC(c(cc1OC23CC2)ccc1NC3=O)=C SRXYBKDQJWUXMA-UHFFFAOYSA-N 0.000 description 1
- AZIWACNBGOIZSN-UHFFFAOYSA-N CCOC(c1ccc2[n](C(OC(C)(C)C)=O)ncc2c1)=C Chemical compound CCOC(c1ccc2[n](C(OC(C)(C)C)=O)ncc2c1)=C AZIWACNBGOIZSN-UHFFFAOYSA-N 0.000 description 1
- ZOOMYZPHPPIHJN-ZWBOLGQQSA-N C[C@@H](C(C=C)C1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3ncc(-c4ccc5c(N(C(c6c7cccc6)=O)C7=O)n[n](C)c5c4)[nH]3)N1C2=O Chemical compound C[C@@H](C(C=C)C1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3ncc(-c4ccc5c(N(C(c6c7cccc6)=O)C7=O)n[n](C)c5c4)[nH]3)N1C2=O ZOOMYZPHPPIHJN-ZWBOLGQQSA-N 0.000 description 1
- JPVHIVPOEQDNTK-MQNRADLISA-N C[C@@H](CC1=CC(c(cc(cc2)Cl)c2-[n]2nnnc2)=C2)[C@@H](c3ncc(-c(ccc(NC(OC(C)(C)C)=O)n4)c4F)[nH]3)N1C2=O Chemical compound C[C@@H](CC1=CC(c(cc(cc2)Cl)c2-[n]2nnnc2)=C2)[C@@H](c3ncc(-c(ccc(NC(OC(C)(C)C)=O)n4)c4F)[nH]3)N1C2=O JPVHIVPOEQDNTK-MQNRADLISA-N 0.000 description 1
- QTCIDMJCIYFPNV-PWFNWSNSSA-N C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnc(Cl)c2)=C2)[C@@H](c3nc(Cl)c(-c(cc4)cc(CC5)c4NC5=O)[nH]3)N1C2=O Chemical compound C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnc(Cl)c2)=C2)[C@@H](c3nc(Cl)c(-c(cc4)cc(CC5)c4NC5=O)[nH]3)N1C2=O QTCIDMJCIYFPNV-PWFNWSNSSA-N 0.000 description 1
- GDCGBHMGBBOJLH-PWFNWSNSSA-N C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnc(Cl)c2)=C2)[C@@H](c3nc(F)c(-c(cc4)cc(CC5)c4NC5=O)[nH]3)N1C2=O Chemical compound C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnc(Cl)c2)=C2)[C@@H](c3nc(F)c(-c(cc4)cc(CC5)c4NC5=O)[nH]3)N1C2=O GDCGBHMGBBOJLH-PWFNWSNSSA-N 0.000 description 1
- JFDMBOUSSVXIFD-BSEYFRJRSA-N C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3nc(Cl)c(-c4ccc(NC(OC(C)(C)C)=O)nc4F)[nH]3)N1C2=O Chemical compound C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3nc(Cl)c(-c4ccc(NC(OC(C)(C)C)=O)nc4F)[nH]3)N1C2=O JFDMBOUSSVXIFD-BSEYFRJRSA-N 0.000 description 1
- QWUAALIIBNHVOF-MYODQAERSA-N C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3nc(F)c(-c(nc4OC5)ccc4NC5=O)[nH]3)N1C2=O Chemical compound C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3nc(F)c(-c(nc4OC5)ccc4NC5=O)[nH]3)N1C2=O QWUAALIIBNHVOF-MYODQAERSA-N 0.000 description 1
- ONULFZDNGJTJIR-ZOKDDAQRSA-N C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3nc(F)c(-c4ccc5c(N(C(c6c7cccc6)=O)C7=O)n[n](C)c5c4)[nH]3)N1C2=O Chemical compound C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3nc(F)c(-c4ccc5c(N(C(c6c7cccc6)=O)C7=O)n[n](C)c5c4)[nH]3)N1C2=O ONULFZDNGJTJIR-ZOKDDAQRSA-N 0.000 description 1
- NMBGJCYUSHPHQT-RZFZLAGVSA-N C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3nc(F)c(-c4ccc5c(N)n[n](C)c5c4)[nH]3)N1C2=O Chemical compound C[C@@H](CC1=CC(c2cc(Cl)ccc2-[n]2nnnc2)=C2)[C@@H](c3nc(F)c(-c4ccc5c(N)n[n](C)c5c4)[nH]3)N1C2=O NMBGJCYUSHPHQT-RZFZLAGVSA-N 0.000 description 1
- UJFLQCFUGZTITD-RULNZOCKSA-N C[C@@H](CC1=NC(c2cc(Cl)ccc2-[n]2nnc(Cl)c2)=C2)[C@@H](c3nc(F)c(-c4ccc5c(N)n[o]c5c4)[nH]3)N1C2=O Chemical compound C[C@@H](CC1=NC(c2cc(Cl)ccc2-[n]2nnc(Cl)c2)=C2)[C@@H](c3nc(F)c(-c4ccc5c(N)n[o]c5c4)[nH]3)N1C2=O UJFLQCFUGZTITD-RULNZOCKSA-N 0.000 description 1
- OYLGROMBFCUTBI-MCFWBGNESA-N C[C@@H](CC1=NC(c2cc(Cl)ccc2-[n]2nnc(Cl)c2)=C2)[C@@H](c3ncc(-c4ccc5c(N)n[o]c5c4)[nH]3)N1C2=O Chemical compound C[C@@H](CC1=NC(c2cc(Cl)ccc2-[n]2nnc(Cl)c2)=C2)[C@@H](c3ncc(-c4ccc5c(N)n[o]c5c4)[nH]3)N1C2=O OYLGROMBFCUTBI-MCFWBGNESA-N 0.000 description 1
- YXYNNFWXQVBZEN-UHFFFAOYSA-N Cc(c(-[n]1nnnc1)ccc1Cl)c1F Chemical compound Cc(c(-[n]1nnnc1)ccc1Cl)c1F YXYNNFWXQVBZEN-UHFFFAOYSA-N 0.000 description 1
- ALEFHFGSCWYALZ-UHFFFAOYSA-N Cc(c(-[n]1nnnc1)ccc1F)c1F Chemical compound Cc(c(-[n]1nnnc1)ccc1F)c1F ALEFHFGSCWYALZ-UHFFFAOYSA-N 0.000 description 1
- KRYQSDCIOZEBRL-UHFFFAOYSA-N Cc(cc(cc1)Cl)c1-[n]1nnc(Cl)c1 Chemical compound Cc(cc(cc1)Cl)c1-[n]1nnc(Cl)c1 KRYQSDCIOZEBRL-UHFFFAOYSA-N 0.000 description 1
- HDRLZAYHRBWEMI-UHFFFAOYSA-N Cc(cc1CC2CC3CC3)ccc1NC2=O Chemical compound Cc(cc1CC2CC3CC3)ccc1NC2=O HDRLZAYHRBWEMI-UHFFFAOYSA-N 0.000 description 1
- CONNFXWQGDJYBZ-UHFFFAOYSA-N Cc1c(C(F)F)ccc(Cl)c1 Chemical compound Cc1c(C(F)F)ccc(Cl)c1 CONNFXWQGDJYBZ-UHFFFAOYSA-N 0.000 description 1
- HGTPZUGWCWPFOP-UHFFFAOYSA-N Cc1cc(C#N)ccc1-[n]1nnnc1 Chemical compound Cc1cc(C#N)ccc1-[n]1nnnc1 HGTPZUGWCWPFOP-UHFFFAOYSA-N 0.000 description 1
- ZAGDBLVKXMLMGP-UHFFFAOYSA-N Cc1cc(Cl)ccc1-[n]1nncc1 Chemical compound Cc1cc(Cl)ccc1-[n]1nncc1 ZAGDBLVKXMLMGP-UHFFFAOYSA-N 0.000 description 1
- MGQFDYOSDHEWCT-UHFFFAOYSA-N Cc1cc(Cl)ccc1-[n]1nnnc1 Chemical compound Cc1cc(Cl)ccc1-[n]1nnnc1 MGQFDYOSDHEWCT-UHFFFAOYSA-N 0.000 description 1
- NDZHSPDLTLLMSL-UHFFFAOYSA-N Cc1cc(Cl)ccc1OC(F)(F)F Chemical compound Cc1cc(Cl)ccc1OC(F)(F)F NDZHSPDLTLLMSL-UHFFFAOYSA-N 0.000 description 1
- UTCZBULSGVLTTN-UHFFFAOYSA-N Cc1cc(F)ccc1-[n]1nnnc1 Chemical compound Cc1cc(F)ccc1-[n]1nnnc1 UTCZBULSGVLTTN-UHFFFAOYSA-N 0.000 description 1
- UKCZPAAARJXWOE-UHFFFAOYSA-N O=C(C1(CC1)Oc1c2)Nc1ccc2Br Chemical compound O=C(C1(CC1)Oc1c2)Nc1ccc2Br UKCZPAAARJXWOE-UHFFFAOYSA-N 0.000 description 1
- BDBWPIXISLYKEG-UHFFFAOYSA-N O=C(C=Nc1c2)Nc1ccc2Br Chemical compound O=C(C=Nc1c2)Nc1ccc2Br BDBWPIXISLYKEG-UHFFFAOYSA-N 0.000 description 1
- XTNFJADYKIHAGB-UHFFFAOYSA-N O=C(CBr)c(cc1N=C2)ccc1NC2=O Chemical compound O=C(CBr)c(cc1N=C2)ccc1NC2=O XTNFJADYKIHAGB-UHFFFAOYSA-N 0.000 description 1
- AVPQOLXFGZRUSG-UHFFFAOYSA-N O=C(CBr)c(cc1OC23CC2)ccc1NC3=O Chemical compound O=C(CBr)c(cc1OC23CC2)ccc1NC3=O AVPQOLXFGZRUSG-UHFFFAOYSA-N 0.000 description 1
- FFRYUAVNPBUEIC-UHFFFAOYSA-N O=C1Nc2ccccc2N=C1 Chemical compound O=C1Nc2ccccc2N=C1 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 description 1
- VQCWSOYHHXXWSP-UHFFFAOYSA-N [O-][N+](c(c(F)c1)ccc1Br)=O Chemical compound [O-][N+](c(c(F)c1)ccc1Br)=O VQCWSOYHHXXWSP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention relates to a compound represented by formula (I), its optical isomers and pharmacologically acceptable salts, and the application of the compound as an FXIa inhibitor.
- Thromboembolic disease is a disease caused by abnormal blood clots formed in blood vessels during the survival of humans and animals. There are three reasons for thrombosis: blood vessel damage, blood changes and blood flow stasis; it is a group of complications caused by many different diseases and different reasons. Due to the differences in various underlying diseases and the location of thromboembolism, the clinical manifestations of thrombosis may include myocardial infarction, stroke, deep vein thrombosis (DVT), pulmonary embolism, atrial fibrillation and cerebral infarction, etc.
- VVT deep vein thrombosis
- Myocardial infarction, cerebral infarction, and pulmonary infarction which are mainly caused by embolism and infarction, rank first among various causes of death, claiming nearly 12 million lives in the world each year, which is close to a quarter of the total deaths in the world.
- the coagulation process of human blood is composed of intrinsic pathway, extrinsic pathway and common pathway. It is a kind of fibrin that is activated by a series of coagulation factors and then strengthened and amplified.
- the coagulation cascade The endogenous pathway (also called the contact activation pathway) and the exogenous pathway (also called the tissue factor pathway) initiate the production of coagulation factor Xa (Factor Xa, FXa for short), and then through the common pathway to generate thrombin IIa (Factor IIa for short FIIa) ), and finally form fibrin.
- Procoagulant blood (hemostasis) and anticoagulant (antithrombotic) are opposed to each other in the human blood system and maintain a relative balance. When the function of the anticoagulation and fibrinolysis system in the body is reduced and the blood coagulation and anticoagulation functions are out of balance, coagulation occurs, causing thrombosis or embolism.
- antithrombotic drugs that have been researched and developed mainly include anticoagulants (such as warfarin and heparin), antiplatelet aggregation drugs (such as aspirin and clopidogrel, etc.) and thrombolytic drugs ( Such as urokinase and reteplase) three categories.
- anticoagulants such as warfarin and heparin
- antiplatelet aggregation drugs such as aspirin and clopidogrel, etc.
- thrombolytic drugs Such as urokinase and reteplase
- the new therapeutic drugs show strong Market vitality is a strong competitor of heparin drugs.
- FIIa direct thrombin
- FXa activated coagulation factor Xa
- the use of activated coagulation factor (FXa) inhibitors is growing rapidly because of their efficacy and safety in the prevention and treatment of thromboembolic disorders such as stroke, pulmonary embolism and venous thromboembolism (VTE). .
- VTE venous thromboembolism
- Factor XI is a plasma serine protease necessary to maintain the endogenous pathway. After activation, it generates activated factor XIa (FXIa), which plays a key role in the amplification process of the coagulation cascade.
- FXIa activated factor XIa
- thrombin can feedback and activate FXI, and the activated FXI promotes the production of thrombin in large quantities, thereby amplifying the coagulation cascade. Therefore, drugs targeting the FXI target can block the endogenous pathway and inhibit the amplification of the coagulation cascade, thereby having an antithrombotic effect.
- FXI human coagulation factor XI
- elevated FXI levels are associated with thrombotic diseases
- anti-thrombotic experimental studies of animal FXI deficiency or knockout or inhibition have shown that compared with direct FXa inhibition Inhibition of FXI may reduce the risk of bleeding and is a new target for antithrombotic prevention and treatment.
- FXI gene knockout mice can survive healthy, and their fecundity and hemostatic function are no different from wild mice. They also show activated partial thromboplastin time (aPTT) prolonged and prothrombin like FXI-deficient patients. Time (prothrombin time, T) is normal. Knockout mouse FXI gene can inhibit arterial and venous thrombosis.
- the antithrombotic effect is equivalent to or even more effective than high-dose heparin, and is better than other drugs such as aspirin, clopidogrel or agar Traban is more effective; moreover, these antithrombotic drugs may cause a small amount of bleeding, and the tail bleeding time of mice with the FXI gene knocked out is no different from that of the wild type.
- FXI may be a target for antithrombotic prevention and treatment with small bleeding side effects.
- the reported FXI inhibitors mainly include monoclonal antibodies, antisense oligonucleotides, small chemical molecules, polypeptides or proteins, and polypeptide mimics.
- Plasma kallikrein is a trypsin-like serine protease present in plasma. It is similar to the coagulation factor XIa gene and has an amino acid sequence similarity of up to 58%. In the blood, most plasma kallikrein exists in the form of a complex with high molecular weight kininogen (HMWK). Plasma kininase is involved in blood coagulation, fibrinolysis and kinin production, and plays a role in blood coagulation and many inflammatory diseases.
- HMWK high molecular weight kininogen
- Plasma kallikrein inhibitors may be used to treat hereditary angioedema (HAE) and advanced diabetic macular edema (advanced diabetic macular edema) and other diseases.
- HAE hereditary angioedema
- Advanced diabetic macular edema advanced diabetic macular edema
- the plasma kininase inhibitor macromolecular protein drug Ecallantide (Kalbitor) has been approved by the FDA for the treatment of HAE. However, no small molecule plasma kininase inhibitor has been approved for marketing. The development of new safe and effective Kallikrein small molecule inhibitor drugs may also satisfy Unmet clinical needs.
- the present invention provides a compound represented by formula (I), its optical isomers and pharmacologically acceptable salts thereof
- Ring A is selected from phenyl and 5- to 6-membered heteroaryl
- Ring B is selected from 5-6 membered heteroaryl groups
- Ring C is selected from phenyl, 5- to 10-membered heteroaryl, benzo 5- to 9-membered heterocycloalkyl, pyrido 5- to 9-membered heterocycloalkyl, and benzo 5- to 9-membered heterocycloalkenyl;
- Ring D is selected from C 3-5 cycloalkyl and 3 to 5 membered heterocycloalkyl;
- R 1 is selected from H, C 1-6 alkyl, C 1-6 heteroalkyl and 5-6 membered heteroaryl, said C 1-6 alkyl, C 1-6 heteroalkyl or 5-6 membered
- the heteroaryl group is optionally substituted by 1, 2 or 3 R;
- R 2 is each independently selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl and C 1-6 heteroalkyl, the C 1-6 alkyl or C 1-6 heteroalkyl is either Choose to be replaced by 1, 2 or 3 R;
- R 3 is selected from H, F, Cl, Br, I, OH, NH 2 , CN and Me;
- R 4 is selected from H, F, Cl, Br, I, OH, NH 2 , CN, COOH, CH 2 OH and C 1-6 alkyl;
- R 5 is independently selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl and C 1-6 heteroalkyl, the C 1-6 alkyl or C 1-6 heteroalkyl is optionally substituted with 1, 2 or 3 R;
- R 6 is independently selected from H, halogen, OH, NH 2 , CN, COOH, C 1-6 alkyl and C 1-6 heteroalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl or Optionally substituted by 1, 2 or 3 R;
- Y is selected from N and C (R 7 );
- R 7 is selected from H, F, Cl, Br, I, OH, NH 2 , CN, C 1-6 alkyl and C 1-6 heteroalkyl, said C 1-6 alkyl or C 1-6 hetero
- the alkyl group is optionally substituted with 1, 2 or 3 R;
- n 0, 1, 2 and 3;
- n is selected from 0, 1, 2 and 3;
- x is selected from 0, 1, 2 and 3;
- z is selected from 0, 1 and 2;
- R is independently selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylamino, C 3-6 cycloalkyl, the C 1-6 alkyl, C 1- 6 Alkoxy, C 1-6 alkylthio, C 1-6 alkylamino or C 3-6 cycloalkyl is optionally substituted with 1, 2 or 3 R';
- R' is selected from H, F, Cl, Br, I, OH, NH 2 and CH 3 ;
- the above-mentioned R is selected from H, F, Cl, Br, I, OH, NH 2 , COOH, CF 3 , CF 2 H, CN, CH 3 O, CH 3 CH 2 O, And Me, the remaining variables are as defined in the present invention.
- the above-mentioned R 1 is selected from H, C 1-3 alkyl, C 1-3 heteroalkyl, tetrazolyl and 1,2,3-triazolyl, the tetrazolyl or
- the 1,2,3-triazolyl is optionally substituted by R
- the C 1-3 alkyl or C 1-3 heteroalkyl is optionally substituted by 1, 2 or 3 R, and the remaining variables are as defined in the present invention .
- the above-mentioned R 1 is selected from H, C 1-3 alkyl, C 1-3 alkoxy, Said Optionally substituted by R, the C 1-3 alkyl group or C 1-3 alkoxy group is optionally substituted by 1, 2 or 3 R, and the remaining variables are as defined in the present invention.
- R 1 is selected from H, -CHF 2 , -OCF 3 ,
- the remaining variables are as defined in the present invention.
- the above-mentioned R 2 is independently selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, and C 1-3 alkoxy.
- the C 1-3 alkyl Or C 1-3 alkoxy is optionally substituted with 1, 2 or 3 R, and the remaining variables are as defined in the present invention.
- R 2 is independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me and The remaining variables are as defined in the present invention.
- the aforementioned ring B is selected from pyrrolyl, imidazolyl, 1,2,4-triazolyl and pyridyl, and the remaining variables are as defined in the present invention.
- R 5 is independently selected from H, F, Cl, Br, OH, NH 2 , Me, CN and The remaining variables are as defined in the present invention.
- the above-mentioned ring C is selected from thienyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indazolyl, isoindolin-1-onyl, quinolinyl , Isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, quinolin-2(1H)-keto, benzisoxazolyl, 1H-benzo[d]imidazolyl, dihydro Indole-2-onyl, indolin-1-onyl, 3,4-dihydroquinoline-2(1H)-onyl, quinoline-2(1H)-onyl, 1H-pyrido [2,3-b][1,4]oxazine-2(3H)-keto, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl
- the above-mentioned R 6 is independently selected from H, halogen, OH, NH 2 , CN, COOH, C 1-3 alkyl, C 1-3 heteroalkyl and C 3-6 cycloalkyl, the C 1-3 alkyl, C 1-3 heteroalkyl or C 3-6 cycloalkyl is optionally Replace with 1, 2 or 3 R, and the remaining variables are as defined in the present invention.
- R 6 is independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, The remaining variables are as defined in the present invention.
- the aforementioned ring D is selected from cyclopropyl, cyclobutyl, azetidinyl, oxetanyl and pyrrolidinyl, and the remaining variables are as defined in the present invention.
- the above-mentioned compound, its optical isomer and its pharmacologically acceptable salt are selected from
- R 1 is as defined above;
- R 2 is as defined above;
- R 3 is as defined above;
- R 4 is as defined above;
- R 5 is as defined above;
- R 6 is as defined above;
- x and Y are as defined above;
- Ring B is as defined above;
- Ring C is as defined above.
- the above-mentioned compound, its optical isomer and its pharmacologically acceptable salt are selected from
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , x, Y, ring B, and ring C are as defined above.
- the above-mentioned compound, its optical isomer and its pharmacologically acceptable salt are selected from
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , x, Y, ring B, and ring C are as defined above.
- the present invention also provides compounds of the following formula, their optical isomers and their pharmacologically acceptable salts, which are selected from
- the present invention also provides a pharmaceutical composition comprising the compound as described above or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, diluents or excipients.
- the present invention also proposes the use of the aforementioned compound or its pharmaceutically acceptable salt or the aforementioned pharmaceutical composition in the preparation of FXIa inhibitors.
- the present invention also proposes the use of the aforementioned compound or its pharmaceutically acceptable salt or the aforementioned pharmaceutical composition in the preparation of a medicine for preventing and/or treating FXIa factor-mediated diseases.
- the above-mentioned FXIa factor-mediated diseases are selected from cardiovascular and cerebrovascular diseases.
- the above-mentioned cardiovascular and cerebrovascular diseases are selected from thromboembolic diseases.
- the above-mentioned thromboembolic disease is selected from the group consisting of hereditary angioedema, advanced diabetic macular edema, myocardial infarction, angina pectoris, reocclusion and restenosis after angioplasty or aortic coronary bypass , Diffuse intravascular coagulation, stroke, transient ischemic attack, peripheral arterial occlusive disease, pulmonary embolism or deep vein thrombosis.
- the present invention also provides a method for treating FXIa factor-mediated diseases, the method comprising administering to patients suffering from FXIa factor-mediated diseases a therapeutically effective amount of the aforementioned compound or Its pharmaceutically acceptable salt or therapeutically effective amount of the aforementioned pharmaceutical composition.
- pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms that are within the scope of reliable medical judgment and are suitable for use in contact with human and animal tissues , Without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable salt refers to a salt of the compound of the present invention, which is prepared from a compound with specific substituents discovered in the present invention and a relatively non-toxic acid or base.
- the base addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of base in a pure solution or a suitable inert solvent.
- Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salt or similar salts.
- the acid addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of acid in a pure solution or a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, hydrogen carbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts, the organic acid includes such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid and methanesulfonic acid; also include salts of amino acids (such as arginine, etc.) , And salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic and acidic
- the pharmaceutically acceptable salt of the present invention can be synthesized from the parent compound containing acid or base by conventional chemical methods. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of appropriate base or acid in water or an organic solvent or a mixture of both.
- the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers Isomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures, such as enantiomers or diastereomer-enriched mixtures, all of these mixtures belong to this Within the scope of the invention.
- Additional asymmetric carbon atoms may be present in substituents such as alkyl. All these isomers and their mixtures are included in the scope of the present invention.
- enantiomer or “optical isomer” refers to stereoisomers that are mirror images of each other.
- cis-trans isomer or “geometric isomer” is caused by the inability to rotate freely because of double bonds or single bonds of ring-forming carbon atoms.
- diastereomer refers to a stereoisomer in which a molecule has two or more chiral centers and the relationship between the molecules is not mirror images.
- wedge-shaped solid line keys And wedge-shaped dashed key Represents the absolute configuration of a solid center, with a straight solid line key And straight dashed key Indicates the relative configuration of the three-dimensional center, using wavy lines Represents a wedge-shaped solid line key Or wedge-shaped dotted key Or use wavy lines Represents a straight solid line key And straight dashed key
- the compound of the present invention may be specific.
- tautomer or “tautomeric form” means that at room temperature, the isomers of different functional groups are in dynamic equilibrium and can be transformed into each other quickly. If tautomers are possible (such as in solution), the chemical equilibrium of tautomers can be reached.
- proton tautomers also called prototropic tautomers
- proton migration such as keto-enol isomerization and imine-ene Amine isomerization.
- Valence isomers include some recombination of bonding electrons to carry out mutual transformation.
- keto-enol tautomerization is the tautomerism between two tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
- the compounds of the present invention may contain unnatural proportions of atomic isotopes on one or more of the atoms constituting the compound.
- compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I), or C-14 ( 14 C).
- deuterated drugs can be formed by replacing hydrogen with heavy hydrogen. The bond formed by deuterium and carbon is stronger than the bond formed by ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs have reduced toxic side effects and increased drug stability. , Enhance the efficacy, extend the biological half-life of drugs and other advantages.
- substituted means that any one or more hydrogen atoms on a specific atom are replaced by substituents, and can include deuterium and hydrogen variants, as long as the valence of the specific atom is normal and the substituted compound is stable of.
- oxygen it means that two hydrogen atoms are replaced. Oxygen substitution will not occur on aromatic groups.
- optionally substituted means that it can be substituted or unsubstituted. Unless otherwise specified, the type and number of substituents can be arbitrary on the basis that they can be chemically realized.
- any variable such as R
- its definition in each case is independent.
- the group may optionally be substituted with up to two Rs, and R has independent options in each case.
- combinations of substituents and/or variants thereof are only permitted if such combinations result in stable compounds.
- linking group When the number of a linking group is 0, such as -(CRR) 0 -, it means that the linking group is a single bond.
- the linking group L is at this time It can be formed by connecting phenyl and cyclopentyl in the same direction as the reading order from left to right It is also possible to connect the phenyl group and the cyclopentyl group in the opposite direction to the reading order from left to right. Combinations of the linking groups, substituents, and/or variants thereof are only permitted if such combinations result in stable compounds.
- the number of atoms in a ring is generally defined as the number of ring members.
- “5-7 membered ring” refers to a “ring” in which 5-7 atoms are arranged around.
- C 1-6 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 6 carbon atoms.
- the C 1-6 alkyl group includes C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 and C 5 alkyl groups, etc.; it may Is monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine).
- C 1-6 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl) , S-butyl and t-butyl), pentyl (including n-pentyl, isopentyl and neopentyl), hexyl, etc.
- C 1-5 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 5 carbon atoms.
- the C 1-5 alkyl group includes C 1-4 , C 1-3 , C 1-2 , C 2-5 , C 2-4 and C 5 alkyl groups, etc.; it may be monovalent (such as methyl) , Divalent (such as methylene) or multivalent (such as methine).
- C 1-5 alkyl examples include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl) , S-butyl and t-butyl), pentyl (including n-pentyl, isopentyl and neopentyl) and so on.
- C 1-4 alkyl is used to denote a linear or branched saturated hydrocarbon group composed of 1 to 4 carbon atoms.
- the C 1-4 alkyl group includes C 1-2 , C 1-3 and C 2-3 alkyl groups, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent ( Such as methine).
- Examples of C 1-4 alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl) , S-butyl and t-butyl) and so on.
- C 1-3 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 3 carbon atoms.
- the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine) .
- Examples of C 1-3 alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
- C 2-8 alkenyl is used to mean a straight-chain or branched hydrocarbon group consisting of 2 to 8 carbon atoms containing at least one carbon-carbon double bond, and a carbon-carbon double bond It can be located at any position of the group.
- the C 2-8 alkenyl group includes C 2-6 , C 2-4 , C 2-3 , C 4 , C 3 and C 2 alkenyl groups, etc.; it may be monovalent, divalent or multivalent.
- Examples of C 2-8 alkenyl include, but are not limited to, vinyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, piperylene, hexadienyl, and the like.
- heteroalkyl by itself or in combination with another term means a stable linear or branched alkyl group or a combination thereof composed of a certain number of carbon atoms and at least one heteroatom or heteroatom group.
- the heteroatoms are selected from B, O, N, and S, where nitrogen and sulfur atoms are optionally oxidized, and nitrogen heteroatoms are optionally quaternized.
- the heteroalkyl group is a C 1-6 heteroalkyl group; in other embodiments, the heteroalkyl group is a C 1-3 heteroalkyl group.
- heteroatom or heteroatom group can be located in any internal position of the heteroalkyl group, including the position of attachment of the alkyl group to the rest of the molecule, but the terms "alkoxy”, “alkylamino” and “alkylthio” (or thioalkyl (Oxy) is a customary expression and refers to those alkyl groups that are connected to the rest of the molecule through an oxygen atom, amino or sulfur atom, respectively.
- Up to two heteroatoms can
- C 1-6 alkoxy refers to those alkyl groups containing 1 to 6 carbon atoms attached to the rest of the molecule through an oxygen atom.
- the C 1-6 alkoxy group includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 and C 3 alkoxy etc. .
- C 1-6 alkoxy examples include but are not limited to methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy) Oxy, s-butoxy and t-butoxy), pentoxy (including n-pentoxy, isopentoxy and neopentoxy), hexoxy and the like.
- C 1-4 alkoxy refers to those alkyl groups containing 1 to 4 carbon atoms that are attached to the rest of the molecule through an oxygen atom.
- the C 1-4 alkoxy group includes C 1-3 , C 1-2 , C 2-4 , C 4 and C 3 alkoxy and the like.
- Examples of C 1-6 alkoxy include but are not limited to methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy) Oxy, s-butoxy and t-butoxy), pentoxy (including n-pentoxy, isopentoxy and neopentoxy), hexoxy and the like.
- C 1-3 alkoxy refers to those alkyl groups containing 1 to 3 carbon atoms attached to the rest of the molecule through an oxygen atom.
- the C 1-3 alkoxy group includes C 1-2 , C 2-3 , C 3 and C 2 alkoxy groups and the like.
- Examples of C 1-3 alkoxy include but are not limited to methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy) and the like.
- C 1-6 alkylamino refers to those alkyl groups containing 1 to 6 carbon atoms attached to the rest of the molecule through an amino group.
- the C 1-6 alkylamino group includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 , C 3 and C 2 alkylamino group Wait.
- C 1-6 alkylamino examples include, but are not limited to -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -N(CH 3 )CH 2 CH 3 , -N(CH 2 CH 3 )( CH 2 CH 3 ), -NHCH 2 CH 2 CH 3 , -NHCH 2 (CH 3 ) 2 , -NHCH 2 CH 2 CH 2 CH 3 and so on.
- C 1-4 alkylamino refers to those alkyl groups containing 1 to 4 carbon atoms attached to the rest of the molecule through an amino group.
- the C 1-4 alkylamino group includes C 1-3 , C 1-2 , C 2-4 , C 4 , C 3 and C 2 alkylamino group and the like.
- C 1-4 alkylamino groups include but are not limited to -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -N(CH 3 )CH 2 CH 3 , -N(CH 2 CH 3 )( CH 2 CH 3 ), -NHCH 2 CH 2 CH 3 , -NHCH 2 (CH 3 ) 2 , -NHCH 2 CH 2 CH 2 CH 3 and so on.
- C 1-3 alkylamino means those alkyl groups containing 1 to 3 carbon atoms attached to the rest of the molecule through an amino group.
- the C 1-3 alkylamino group includes C 1-2 , C 3 and C 2 alkylamino groups and the like.
- Examples of C 1-3 alkylamino groups include, but are not limited to, -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -N(CH 3 )CH 2 CH 3 , -NHCH 2 CH 2 CH 3 ,- NHCH 2 (CH 3 ) 2 and so on.
- C 3-6 cycloalkyl means a saturated cyclic hydrocarbon group composed of 3 to 6 carbon atoms, which is a monocyclic and bicyclic ring system.
- the C 3-6 cycloalkyl includes C 3-5 , C 4-5 and C 5-6 cycloalkyl, etc.; it can be monovalent, divalent or multivalent.
- Examples of C 3-6 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- C 3-5 cycloalkyl means a saturated cyclic hydrocarbon group composed of 3 to 5 carbon atoms, which is a monocyclic ring system, and the C 3-5 cycloalkyl includes C 3 -4 and C 4-5 cycloalkyl, etc.; it can be monovalent, divalent or multivalent.
- Examples of C 3-5 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and the like.
- the term "5-9 membered heterocycloalkyl" by itself or in combination with other terms means a saturated cyclic group consisting of 5 to 9 ring atoms, with 1, 2, 3 or 4 ring atoms.
- heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein nitrogen atoms are optionally quaternized, and nitrogen and sulfur heteroatoms can be optionally oxidized (ie, NO and S(O) p , p Is 1 or 2). It includes monocyclic and bicyclic ring systems, where the bicyclic ring system includes spiro, fused, and bridged rings.
- a heteroatom may occupy the connection position of the heterocycloalkyl group with the rest of the molecule.
- the 5-6 membered heterocycloalkyl group includes 5-membered, 6-membered, 7-membered, 8-membered, and 9-membered heterocycloalkyl.
- Examples of 5-9 membered heterocycloalkyl include, but are not limited to, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.) , Tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1 -Piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithiaalkyl, isoxazolidinyl, isothiazole Alkyl, 1,2-oxazinyl, 1,2-thiazinyl,
- examples of the term “benzo 5-9 membered heterocycloalkyl” as used in the present invention include but are not limited to Etc.
- examples of the term “pyrido 5-9 membered heterocycloalkyl” as used in the present invention include but are not limited to Wait.
- the term "3-5 membered heterocycloalkyl” by itself or in combination with other terms means a saturated monocyclic group consisting of 3 to 5 ring atoms, with 1, 2, 3 or 4 ring atoms Are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein nitrogen atoms are optionally quaternized, and nitrogen and sulfur heteroatoms can be optionally oxidized (ie, NO and S(O) p , p Is 1 or 2).
- a heteroatom may occupy the connection position of the heterocycloalkyl group with the rest of the molecule.
- the 3-5 membered heterocycloalkyl group includes 4-5 membered, 4-membered, and 5-membered heterocycloalkyl groups.
- Examples of 3-5 membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl ( Including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.) or tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.) and the like.
- the term "4-5 membered heterocycloalkyl” by itself or in combination with other terms means a saturated monocyclic group consisting of 4 to 5 ring atoms, with 1, 2, 3 or 4 ring atoms Are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein nitrogen atoms are optionally quaternized, and nitrogen and sulfur heteroatoms can be optionally oxidized (ie, NO and S(O) p , p Is 1 or 2).
- a heteroatom may occupy the connection position of the heterocycloalkyl group with the rest of the molecule.
- the 4-5 membered heterocycloalkyl group includes 4-membered and 5-membered heterocycloalkyl groups.
- Examples of 4-5 membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl ( Including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.) or tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.) and the like.
- the term "3-4 membered heterocycloalkyl” by itself or in combination with other terms means a saturated monocyclic group consisting of 3 to 4 ring atoms, with 1, 2, 3 or 4 ring atoms Are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein nitrogen atoms are optionally quaternized, and nitrogen and sulfur heteroatoms can be optionally oxidized (ie, NO and S(O) p , p Is 1 or 2).
- a heteroatom may occupy the connection position of the heterocycloalkyl group to the rest of the molecule.
- the 3-4 membered heterocycloalkyl group includes 3- and 4-membered heterocycloalkyl groups.
- Examples of 3-4 membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetanyl, thietanyl, and the like.
- the term "3-12 membered heterocycloalkenyl" by itself or in combination with other terms means a partially unsaturated cyclic group consisting of 3 to 12 ring atoms containing at least one carbon-carbon double bond , Its 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms can optionally be Oxidation (ie NO and S(O) p , p is 1 or 2). It includes monocyclic, bicyclic and tricyclic ring systems. The bicyclic and tricyclic ring systems include spiro, fused and bridged rings.
- any ring in this system is non-aromatic.
- a heteroatom may occupy the connection position of the heterocycloalkenyl group with the rest of the molecule.
- the 3-12 membered heterocycloalkenyl includes 3-10 members, 3-8 members, 3-6 members, 3-5 members, 4-6 members, 4-5 members, 5-6 members, 4 members, 5 And 6-membered heterocycloalkenyl, etc. Examples of 3-12 membered heterocycloalkenyl include but are not limited to
- the term "5-9 membered heterocycloalkenyl" by itself or in combination with other terms means a partially unsaturated cyclic group consisting of 5 to 9 ring atoms containing at least one carbon-carbon double bond , Its 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms can optionally be Oxidation (ie NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic ring systems. The bicyclic ring system includes spiro, fused, and bridged rings.
- any ring in this system is non-aromatic.
- a heteroatom may occupy the connection position of the heterocycloalkenyl group with the rest of the molecule.
- the 5-6 membered heterocycloalkenyl includes 5-membered, 6-membered, 7-membered, 8-membered, 9-membered heterocycloalkenyl and the like.
- Examples of 5-9 membered heterocycloalkenyl include but are not limited to When the term “5-9 membered heterocycloalkenyl alkyl" is used in combination with other terms, for example, examples of “benzo 5-9 membered heterocycloalkenyl alkyl" in the present invention include but are not limited to
- 5-12 membered heteroaryl ring and “5-12 membered heteroaryl group” can be used interchangeably in the present invention.
- the term “5-12 membered heteroaryl group” means a ring consisting of 5 to 12 ring atoms. It is composed of a cyclic group with a conjugated ⁇ -electron system in which 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. It can be a monocyclic, fused bicyclic or fused tricyclic system, where each ring is aromatic.
- the nitrogen and sulfur heteroatoms can be optionally oxidized (ie NO and S(O) p , p is 1 or 2).
- the 5-12 membered heteroaryl group can be attached to the rest of the molecule through a heteroatom or a carbon atom.
- the 5-12 membered heteroaryl groups include 5-10 membered, 5-8 membered, 5-7 membered, 5-6 membered, 5 membered and 6 membered heteroaryl groups and the like.
- Examples of the 5-12 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrrolyl, etc.) Azolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5- Oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1, 2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thi
- 5-10 membered heteroaryl ring and “5-10 membered heteroaryl group” can be used interchangeably in the present invention.
- the term “5-10 membered heteroaryl group” means a ring consisting of 5 to 10 A cyclic group composed of atoms with a conjugated ⁇ -electron system, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. It can be a monocyclic, fused bicyclic or fused tricyclic system, where each ring is aromatic.
- the nitrogen and sulfur heteroatoms can be optionally oxidized (ie NO and S(O) p , p is 1 or 2).
- the 5-10 membered heteroaryl group can be attached to the rest of the molecule through a heteroatom or a carbon atom.
- the 5-10 membered heteroaryl groups include 5-8 membered, 5-7 membered, 5-6 membered, 5 membered and 6 membered heteroaryl groups and the like.
- Examples of the 5-10 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrrolyl, etc.) Azolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5- Oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1, 2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thi
- 5-6 membered heteroaryl ring and “5-6 membered heteroaryl group” can be used interchangeably in the present invention.
- the term “5-6 membered heteroaryl group” means a ring consisting of 5 to 6 ring atoms. It is composed of a monocyclic group with a conjugated ⁇ -electron system, in which 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. Where the nitrogen atom is optionally quaternized, the nitrogen and sulfur heteroatoms can be optionally oxidized (ie NO and S(O) p , p is 1 or 2).
- the 5-6 membered heteroaryl group can be attached to the rest of the molecule through a heteroatom or a carbon atom.
- the 5-6 membered heteroaryl group includes 5-membered and 6-membered heteroaryl groups.
- Examples of the 5-6 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrrolyl, etc.) Azolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5- Oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1, 2,
- C n-n+m or C n -C n+m includes any specific case of n to n+m carbons, for example, C 1-12 includes C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , and C 12 , including any range from n to n+m, for example, C 1-12 includes C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12, etc.; in the same way, from n to n +m means the number of atoms in the ring is n to n+m, for example, 3-12 membered ring includes 3-membered ring, 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, 8-membered ring, 9-membered
- leaving group refers to a functional group or atom that can be replaced by another functional group or atom through a substitution reaction (for example, an affinity substitution reaction).
- representative leaving groups include triflate; chlorine, bromine, iodine; sulfonate groups, such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonic acid Esters, etc.; acyloxy groups, such as acetoxy, trifluoroacetoxy and the like.
- protecting group includes but is not limited to "amino protecting group", “hydroxy protecting group” or “thiol protecting group”.
- amino protecting group refers to a protecting group suitable for preventing side reactions at the amino nitrogen position.
- Representative amino protecting groups include, but are not limited to: formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc) ; Arylmethyloxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethyloxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di -(4'-Methoxyphenyl)methyl; silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethyls
- hydroxy protecting group refers to a protecting group suitable for preventing side reactions of the hydroxyl group.
- Representative hydroxy protecting groups include but are not limited to: alkyl groups, such as methyl, ethyl, and tert-butyl; acyl groups, such as alkanoyl groups (such as acetyl); arylmethyl groups, such as benzyl (Bn), p-methyl Oxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl groups such as trimethylsilyl (TMS) and tert-butyl Dimethylsilyl (TBS) and so on.
- alkyl groups such as methyl, ethyl, and tert-butyl
- acyl groups such as alkanoyl groups (such as acetyl)
- arylmethyl groups such as benzyl (Bn), p-methyl Oxybenzyl (P
- treatment refers to the administration of one or more drug substances, particularly the compound of formula (I) described herein and/or pharmaceutically acceptable compounds thereof, to an individual suffering from a disease or having symptoms of the disease
- the salt is used to cure, alleviate, alleviate, change, treat, ameliorate, improve or affect the disease or the symptoms of the disease.
- prevention refers to the administration of one or more drug substances, particularly the compound of formula (I) described herein and/or a pharmaceutically acceptable salt thereof, to an individual who is susceptible to the disease, To prevent individuals from suffering from the disease.
- the terms “treating”, “contacting” and “reacting” refer to the addition or mixing of two or more reagents under appropriate conditions to produce the indicated and/or desired product. It should be understood that the reaction to produce the shown and/or desired product may not necessarily come directly from the combination of the two reagents initially added, that is, one or more intermediates may be present in the mixture. The body ultimately leads to the formation of the indicated and/or desired product.
- the term "effective amount” as used in the present invention refers to an amount generally sufficient to produce a beneficial effect on an individual.
- Conventional methods such as modeling, dose escalation studies, or clinical trials
- conventional influencing factors such as the method of administration, the pharmacokinetics of the compound, the severity and course of the disease, the individual's medical history, the individual's health, the individual The degree of response to the drug, etc.
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those well known to those skilled in the art Equivalent alternatives, preferred implementations include but are not limited to the embodiments of the present invention.
- the solvent used in the present invention is commercially available.
- the present invention uses the following acronyms: NaHMDS stands for sodium bis(trimethylsilyl)amide, LiHMDS stands for lithium bis(trimethylsilyl)amide, and DMPU stands for 1,3-dimethyl-3,4,5 , 6-Tetrahydro-2-pyrimidinone, h stands for hours, min stands for minutes.
- HPLC analysis conditions used in the present invention Chromatographic column: waters XSelect CSH C18 4.6*100mm, 3.5um; mobile phase: [water (0.01% trifluoroacetic acid)-acetonitrile (0.01% trifluoroacetic acid)], B%: 5 % ⁇ 95%; flow rate: 1.2mL/min, column temperature: 40°C.
- the aqueous phase was extracted with ethyl acetate (300mL ⁇ 2).
- reaction solution was warmed to room temperature, stirred for 12h, and quenched by adding saturated aqueous sodium sulfite solution (1mL), the solvent was removed under reduced pressure, water (10mL) and ethyl acetate (10mL) were added, the organic phase was separated, and the aqueous phase was treated with ethyl acetate.
- the ester (10 mL ⁇ 3) was extracted, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to dryness to obtain crude product C-3, which was directly used in the next reaction without further purification.
- compound C-3 (1.0 g, 2.8 mmol) was dissolved in methanol (20 mL), and a hexane solution of trimethylsilanated diazomethane (2.0 M) (14 mL, 28 mmol) was added.
- compound H-1 (1 g, 3.5 mmol) was dissolved in tetrahydrofuran (10 mL), borane tetrahydrofuran complex (129.2 mg, 0.32 mmol) was added, and the reaction was raised to room temperature and stirred for 60 h.
- the reaction solution was quenched with 1.0M hydrochloric acid (8 mL), stirred for 1 h, the reaction solution was diluted with water (40 mL), and extracted with ethyl acetate (20 mL ⁇ 2).
- compound H-3 (0.9 g, 3.38 mmol) was dissolved in dichloromethane (10 mL), and diethylaminosulfur trifluoride (817 mg, 5.07 mmol) was added, and the mixture was stirred at this temperature for 2 h.
- reaction solution was cooled to room temperature, diluted with ethyl acetate (10 mL), separated by adding water (10 mL), and the aqueous phase was extracted with ethyl acetate (10 mL ⁇ 3).
- the organic phases were combined, washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
- compound J-1 (20.4g, 182mmol) was dissolved in N,N-dimethylformamide (160mL), and N-iodosuccinimide (45.0g, 200mmol) was added in batches, Warm to room temperature and stir for 3h.
- compound K-2 (2.46g, 7.19mmol) was dissolved in dichloromethane (50mL), and 4-dimethylaminopyridine (264mg, 2.16mmol) and di-tert-butyl dicarbonate (1.88g, 8.63mmol, 1.98mL), the reaction was stirred at room temperature for 16h.
- compound L-2 is processed to obtain compound Int-L.
- compound M-2 is processed to obtain compound Int-M.
- compound N-4 is processed to obtain compound Int-N.
- compound O-2 is processed to obtain compound Int-O.
- compound Q-1 is processed to obtain compound Int-Q.
- Acetone oxime (6g, 30.0mmol) was dissolved in N,N-dimethylformamide (60mL), potassium tert-butoxide (3.7g, 33.0mmol) was added, stirred at room temperature for 30min, and S-1 (2.4g, 33.0 mmol), the reaction was stirred at room temperature for 1 h.
- the reaction solution was quenched with saturated ammonium chloride solution (100mL), diluted with methyl tert-butyl ether (100mL) and water (50mL), separated, and the aqueous phase was extracted with methyl tert-butyl ether (50mL x 2).
- the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain crude S-2, which was directly used in the next reaction without further purification.
- compound S-4 is processed to obtain compound Int-S.
- compound V-3 (669.6g, 1.53mol) was dissolved in N-methylpyrrolidone (4.70L), and zinc cyanide (269.1g, 2.29mol) and tetrakistriphenylphosphine palladium (176.6 g, 152.8mmol), the reaction was heated to 105°C and stirred for 6h.
- compound N-4 is processed to obtain compound Int-W.
- compound X-2 (2.2 g, 10.0 mmol) was dissolved in hydrobromic acid (40 mL, 44% aqueous solution), and the reaction was heated to 100° C. and stirred for 16 h. The system was concentrated under reduced pressure to remove the solvent to obtain crude product X-3, which was directly used in the next reaction without further purification.
- compound X-5 is processed to obtain compound Int-X.
- compound Y-1 (2.50g, 15.7mmol) and triethylamine (22mL, 157.1mmol) were dissolved in acetonitrile (10mL) and water (5mL), and thioglycolic acid (1.41mL, 20.4mmol) was added dropwise The reaction was heated to 70°C and stirred for 16h.
- compound Y-2 (3.16g, 13.67mmol) and potassium carbonate (17.4g, 125.6mmol) were dissolved in water (60mL) and slowly added dropwise to sodium hydroxide (16.4g, 94.2mmol) in water (40mL) ) Solution, the reaction was stirred at 30°C for 16h. Add concentrated hydrochloric acid to the system to adjust the pH to 3.0, continue stirring for 1 hour, cool to 0°C, and filter to obtain crude Y-3.
- compound Y-4 (1.62g, 9.57mmol) was dissolved in dichloromethane (40mL), and N-bromosuccinimide (1.45g, 8.14mmol) was added to react Stir at this temperature for 1 h.
- compound Y-6 is processed to obtain compound Int-Y.
- compound Z-3 (1g, 3.98mmol) was dissolved in pyridine (10mL), 4-dimethylaminopyridine (146mg, 1.19mmol) and di-tert-butyl dicarbonate (1.04g, 4.78mmol) were added , 1.10mL), the reaction was stirred at 80°C for 16h.
- compound Z-4 is processed to obtain compound Int-Z.
- compound AB-2 is processed to obtain compound Int-AB.
- compound AC-2 is processed to obtain compound Int-AC.
- the compound AD-2 is processed to obtain the compound Int-AD.
- compound AE-1 (2.20g, 10.0mmol) and triethylamine (14mL, 100.0mmol) were dissolved in acetonitrile (7mL) and water (3.5mL), and thioglycolic acid (0.9mL, 13.0mmol) was added dropwise The reaction was heated to 70°C and stirred for 16h.
- compound AE-2 (2.48g, 8.49mmol) and potassium carbonate (9.4g, 67.92mmol) were dissolved in water (30mL), and the sodium hydroxide (8.87g, 50.94mmol) was slowly added dropwise. Water (20 mL) solution, the reaction was stirred at this temperature for 16 h. Add concentrated hydrochloric acid to the system to adjust the pH to 3.0. Continue to stir for 1h. The system was cooled to 0°C, filtered, and the solid was dried under vacuum to obtain crude product AE-3, which was directly used in the next reaction without further purification.
- compound AE-3 is processed to obtain compound Int-AE.
- the compound AF-2 is treated as described in the synthesis method of K-1 ⁇ Int-K in the preparation of intermediate Int-K to obtain compound Int-AF.
- reaction solution was poured into ice water (10mL), extracted with ethyl acetate (20mL ⁇ 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
- the compound AG-2 is processed to obtain the compound Int-AG.
- compound AH-3 is processed to obtain compound Int-AH.
- compound AI-1 is processed to obtain compound Int-AI.
- compound AL-3 is processed to obtain compound Int-AL.
- compound AM-5 is processed to obtain compound Int-AM.
- compound AN-1 (1.57 g, 7.77 mmol) was dissolved in tetrahydrofuran (30 mL), triphosgene (2.31 g, 7.77 mmol) was added, and the reaction was stirred at room temperature for 1 h. The system was quenched with water (30mL), extracted with ethyl acetate (20mL x 3), the organic phases were combined, washed with saturated brine (50mL), dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound AN-2 , Used directly in the next reaction without further purification.
- compound AN-2 is processed to obtain compound Int-AN.
- compound AO-1 is processed to obtain compound Int-AO.
- compound AP-4 is processed to obtain compound Int-AP.
- compound AQ-1 is processed to obtain compound Int-AQ.
- compound AR-3 (23.5 g, 57.0 mmol) was dissolved in ethanol (300 mL), 2.0 M sodium hydroxide aqueous solution (150 mL) was slowly added dropwise, and the reaction was stirred under reflux for 2 h.
- the system was cooled to 0°C, 1.0M dilute hydrochloric acid was added to slowly adjust the pH to 4.0, extracted with ethyl acetate (500 mL ⁇ 3), the organic phases were combined, dried with anhydrous sodium sulfate, and filtered.
- compound AR-6 is processed to obtain compound Int-AR.
- compound AE-1 (6.60g, 30.0mmol) was dissolved in N,N-dimethylformamide (70.0mL), sodium methyl mercaptan (5.04g, 72.0mol) was added, and the reaction was carried out at this temperature Stir for 2h.
- the reaction solution was poured into ice water (50.0 mL), a yellow solid precipitated, filtered, and the solid was dried to obtain the crude product AS-1, which was directly used in the next reaction without further purification.
- compound AS-1 (3.60g, 14.5mmol) was dissolved in water/dichloromethane/acetonitrile (15.0mL/9.00mL/9.00mL) mixed solvent, and sodium periodate (12.4g, 58.0mmol) and tetra-n-propylammonium perruthenate (1.02g, 2.90mmol), and the reaction was stirred at room temperature for 3h.
- compound AT-2 (3.50g, 27.53mmol) was dissolved in tetrahydrofuran (30.0mL), N,N'-carbonyldiimidazole (8.04g, 49.56mmol) was added, and the reaction was heated to 60°C and stirred for 2h.
- compound AT-5 is processed to obtain compound Int-AT.
- compound AU-3 is processed to obtain compound Int-AU.
- the compound 2,2,6,6-tetramethylpiperidine (20.1g, 142.4mmol) was dissolved in tetrahydrofuran (120mL), and a tetrahydrofuran solution of n-butyllithium (89.0mL, 142.4mmol, 1.6M), stirred at this temperature for 1 hour, cooled to -70°C, added compound AV-1 (25g, 130.2mmol) in tetrahydrofuran solution (250mL), continued stirring at -70°C for 1 hour, and added dropwise N, N -Dimethylformamide (20 mL), the reaction was slowly warmed to room temperature and stirred for 16 h.
- compound AV-6 is processed to obtain compound Int-AV.
- compound AW-2 is processed to obtain compound Int-AW.
- compound AX-2 (2.67g, 10.0mmol) was dissolved in tetrahydrofuran (30mL), and bis(trimethylsilyl) lithium amide (11.4mL, 11.4mmol, 1.0M tetrahydrofuran) was slowly added dropwise Solution), the mixture was stirred at this temperature for 0.5h, and methyl iodide (1.56g, 11.0mmol) was slowly added dropwise. After the addition was completed, the reaction was slowly raised to room temperature and stirred for 16h. The reaction solution was quenched by adding water (50mL) and extracted with ethyl acetate (50mL ⁇ 2).
- compound AX-5 is processed to obtain compound Int-AX.
- compound AY-2 (690mg, 2.81mmol) was dissolved in N,N-dimethylformamide (4mL), bromosuccinimide (474mg, 2.67mmol) was added, and the reaction was at room temperature Stir for 40h.
- compound AY-3 is processed to obtain compound Int-AY.
- the synthesis of compounds 11-14 can be done through the synthesis method described in the preparation of compound 1 ⁇ the preparation of compound 2, using intermediates Int-D, Int-E, Int-F, and Int-I as raw materials, respectively, and intermediate Int- J reaction preparation.
- the analysis data is shown in Table 2 below.
- the reaction solution was diluted with ethyl acetate (10 mL), a saturated aqueous solution of sodium sulfite (10 mL) was added, stirred for 10 min, water (10 mL) was added, and the layers were separated. The aqueous layer was extracted with ethyl acetate (10 mL ⁇ 3). The organic phases were combined, washed with 1.0 M aqueous hydrochloric acid solution (10 mL), saturated sodium bicarbonate aqueous solution (10 mL), saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
- Compounds 18-21 can be synthesized by the synthetic method described in the preparation of compound 16, with commercially available compounds 4-bromoacetyl-2-fluorobenzonitrile, 5-(bromoacetyl)-2-oxindoline and intermediates Int-L and Int-N are raw materials, which are prepared by reacting with intermediate Int-C respectively.
- the analysis data is shown in Table 3 below.
- the synthesis of compound 22 can be prepared by the synthetic method described in the preparation of compound 17, using compound 21 as a raw material.
- the analysis data are as follows.
- the synthesis of compounds 23-28 can be done by the synthesis method described in the preparation of compound 1, using intermediates Int-M, Int-O, Int-P, Int-Q, Int-R and Int-S as raw materials. Int-C reaction preparation.
- Table 4 The analysis data is shown in Table 4 below.
- Table 4 The structure and analysis data of the compounds of Examples 23-28
- the synthesis of compound 29 can be prepared by the reaction of intermediate Int-C and intermediate Int-S by the synthesis method described in Preparation of Compound 1 ⁇ Preparation of Compound 2.
- the analysis data is as follows.
- the synthesis of compound 30 can be prepared by the synthesis method described in the preparation of compound 16, using Int-D and 16-1 as raw materials.
- the analysis data are as follows.
- the synthesis of compound 31 can be prepared by the synthesis method described in the preparation of compound 17, using compound 30 as a raw material.
- the analysis data are as follows.
- the synthesis of compound 32 can be prepared by the synthesis method described in the preparation of compound 15 using Int-D and Int-K as raw materials.
- the analysis data are as follows.
- the synthesis of compound 34 can be prepared by the synthetic method described in the preparation of compound 15, using Int-C and Int-T as raw materials.
- the analysis data are as follows.
- the reaction solution was diluted with dichloromethane (20mL) and water (10mL), separated, the aqueous phase was extracted with dichloromethane (10mL ⁇ 3), the organic phases were combined, and then subjected to saturated sodium bicarbonate solution (10mL) and saturated salt Wash with water (10 mL), dry with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure.
Abstract
Description
编号 | FXIa IC 50 | 编号 | FXIa IC 50 |
实施例1 | 6.50 | 实施例68 | 3.54 |
实施例2 | 6.70 | 实施例69 | 0.36 |
实施例14 | 2.84 | 实施例70 | 2.16 |
实施例15 | 0.82 | 实施例75 | 5.27 |
实施例16 | 4.74 | 实施例76 | 0.76 |
实施例17 | 0.83 | 实施例77 | 3.18 |
实施例20 | 6.30 | 实施例78 | 1.41 |
实施例24 | 8.65 | 实施例79 | 1.02 |
实施例28 | 0.82 | 实施例80 | 6.36 |
实施例29 | 0.50 | 实施例81 | 5.37 |
实施例31 | 4.63 | 实施例82 | 4.84 |
实施例32 | 2.72 | 实施例83 | 0.83 |
实施例33 | 0.85 | 实施例86 | 0.31 |
实施例34 | 11.85 | 实施例87 | 5.04 |
实施例36 | 3.34 | 实施例88 | 2.85 |
实施例41 | 3.26 | 实施例89 | 12.49 |
实施例42 | 8.71 | 实施例90 | 6.33 |
实施例48 | 3.93 | 实施例91 | 3.93 |
实施例49 | 6.40 | 实施例92 | 4.24 |
实施例50 | 7.02 | 实施例95 | 2.47 |
实施例55 | 5.18 | 实施例96 | 5.24 |
实施例57 | 8.32 | 实施例97 | 1.19 |
实施例58 | 3.25 | 实施例101 | 3.58 |
实施例59 | 1.41 | ||
实施例62 | 6.76 | ||
实施例64 | 4.78 |
编号 | CT2.0(μM) | 编号 | CT2.0(μM) |
实施例1 | 1.72 | 实施例68 | 0.65 |
实施例2 | 0.55 | 实施例69 | 0.86 |
实施例14 | 0.55 | 实施例70 | 1.32 |
实施例15 | 0.47 | 实施例75 | 1.42 |
实施例16 | 0.63 | 实施例76 | 0.43 |
实施例17 | 0.54 | 实施例77 | 0.82 |
实施例20 | 0.88 | 实施例78 | 0.86 |
实施例24 | 0.90 | 实施例79 | 0.72 |
实施例28 | 0.07 | 实施例80 | 3.50 |
实施例29 | 0.37 | 实施例81 | 2.28 |
实施例31 | 2.38 | 实施例82 | 1.04 |
实施例32 | 0.26 | 实施例83 | 0.82 |
实施例33 | 0.69 | 实施例86 | 0.20 |
实施例34 | 0.58 | 实施例87 | 0.67 |
实施例36 | 0.42 | 实施例88 | 0.82 |
实施例41 | 1.20 | 实施例89 | 1.29 |
实施例42 | 1.08 | 实施例90 | 0.63 |
实施例48 | 3.65 | 实施例91 | 2.27 |
实施例49 | 6.86 | 实施例92 | 0.83 |
实施例50 | 3.16 | 实施例95 | 3.76 |
实施例55 | 0.67 | 实施例96 | 0.26 |
实施例57 | 0.54 | 实施例97 | 0.68 |
实施例58 | 1.21 | 实施例101 | 0.51 |
实施例59 | 0.84 | ||
实施例62 | 2.32 | ||
实施例64 | 1.11 |
化合物 | T 1/2(hr) | AUC inf(ng*hr/mL) | Vz(mL/Kg) | Cl(mL/min/kg) |
实施例36 | 1.65 | 6528.72 | 348.72 | 2.66 |
实施例90 | 3.41 | 26929.84 | 179.84 | 0.63 |
化合物 | T 1/2(hr) | C max(ng/mL) | AUC inf(ng*hr/mL) | F(%) |
实施例36 | 1.63 | 709.00 | 3305.90 | 25.32 |
实施例90 | 3.16 | 1830.00 | 17605.06 | 28.4 |
Claims (27)
- 式(Ⅰ)所示化合物、其光学异构体及其药效上可接受的盐,其中,环A选自苯基和5~6元杂芳基;环B选自5~6元杂芳基;环C选自苯基、5~10元杂芳基、苯并5~9元杂环烷基、吡啶并5-9元杂环烷基和苯并5~9元杂环烯烷基;环D选自C 3-5环烷基和3~5元杂环烷基;R 1选自H、C 1-6烷基、C 1-6杂烷基和5~6元杂芳基,所述C 1-6烷基、C 1-6杂烷基或5~6元杂芳基任选被1、2或3个R取代;R 2分别独立地选自H、卤素、OH、NH 2、CN、C 1-6烷基和C 1-6杂烷基,所述C 1-6烷基或C 1-6杂烷基任选被1、2或3个R取代;R 3选自H、F、Cl、Br、I、OH、NH 2、CN和Me;R 4选自H、F、Cl、Br、I、OH、NH 2、CN、COOH、CH 2OH和C 1-6烷基;Y选自N和C(R 7);R 7选自H、F、Cl、Br、I、OH、NH 2、CN、C 1-6烷基和C 1-6杂烷基,所述C 1-6烷基或C 1-6杂烷基任选被1、2或3个R取代;m选自0、1、2和3;n选自0、1、2和3;x选自0、1、2和3;z选自0、1和2;R分别独立地选自H、卤素、OH、NH 2、CN、 C 1-6烷基、C 1-6烷氧基、C 1-6烷硫基、 C 1-6烷氨基、C 3-6环烷基,所述C 1-6烷基、C 1-6烷氧基、C 1-6烷硫基、C 1-6烷氨基或C 3-6环烷基任选被1、2或3个R’取代;R’选自H、F、Cl、Br、I、OH、NH 2和CH 3;上述3~5元杂环烷基、5~6元杂环烷基、5~9元杂环烯烷基、5-9元杂环烷基、5~6元杂芳基、5~10元杂芳基、C 1-6杂烷基或C 1-6杂环烷基包含1、2或3个独立选自-O-、-NH-、-S-、-C(=O)-、-C(=O)O-、-S(=O)-、-S(=O) 2-和N的杂原子或杂原子团。
- 根据权利要求1或2所述化合物、其光学异构体及其药效上可接受的盐,其中,R 1选自H、C 1-3烷基、C 1-3杂烷基、四唑基和1,2,3-三唑基,所述四唑基或1,2,3-三唑基任选被R取代,所述C 1-3烷基或C 1-3杂烷基任选被1、2或3个R取代。
- 根据权利要求1或2所述化合物、其光学异构体及其药效上可接受的盐,其中,R 2分别独立地选自H、卤素、OH、NH 2、CN、C 1-3烷基和C 1-3烷氧基,所述C 1-3烷基或C 1-3烷氧基任选被1、2或3个R取代。
- 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐,其中,环B选自吡咯基、咪唑基、1,2,4-三唑基和吡啶基。
- 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐,其中,环C选自噻吩基、苯基、吡啶基、嘧啶基、哒嗪基、吡嗪基、吲唑基、异吲哚啉-1-酮基、喹啉基、异喹啉基、1,2,3,4-四氢喹啉基、喹啉-2(1H)-酮基、苯并异恶唑基、1H-苯并[d]咪唑基、二氢吲哚-2-酮基、二氢吲哚-1-酮基、3,4-二氢喹啉-2(1H)-酮基、喹啉-2(1H)-酮基、1H-吡啶并[2,3-b][1,4]恶嗪-2(3H)-酮基、3,4-二氢-2H-苯并[b][1,4]恶嗪基、3,4-二氢-2H-苯并[b][1,4]噻嗪基2H苯并[b][1,4]恶嗪-3(4H)-酮基、3,4-二氢-1,8-萘啶-2(1H)-酮基、喹喔啉-2(1H)-酮基、螺[苯并[b][1,4]恶嗪-2,1'-环丙烷]-3(4H)-酮基、1,4-二氢-2H-苯并[d][1,3]恶嗪-2-酮基、2H苯并[b][1,4]噻嗪-3(4H)-酮基、3,4-二氢-2H-苯并[b][1,4]噻嗪1,1-二氧化物基、1,4-二氢铬烯[4,3-c]吡唑基和4,5-二氢-1H-苯并[g]吲唑基。
- 根据权利要求1所述化合物、其光学异构体及其药效上可接受的盐,其中,环D选自环丙基、环丁基、氮杂环丁基、氧杂环丁基和吡咯烷基。
- 一种药物组合物,其中,所述药物组合物包含如权利要求1~20任意一项所述化合物或其药学上可药用盐。
- 根据权利要求22所述的药物组合物,所述药物组合物进一步包含一种或多种药学上可接受的载体、稀释剂或赋形剂。
- 根据权利要求1~20任意一项所述化合物或其可药用盐或根据权利要求22或23所述的药物组合物在制备FXIa抑制剂的应用。
- 根据权利要求1~20任意一项所述化合物或其可药用盐或根据权利要求22或23所述的药物组合物在制备预防和/或治疗FXIa因子介导的疾病的药物中的用途。
- 根据权利要求25所述的用途,其中所述FXIa因子介导的疾病选自心脑血管疾病;任选地,所述心脑血管疾病选自血栓栓塞性疾病;任选地,所述血栓栓塞性疾病选自遗传性血管神经性水肿、晚期糖尿病性黄斑水肿、心肌梗塞、心绞痛、血管成型术或主动脉冠状动脉分流术后的再阻塞和再狭窄、弥散性血管内凝血、中风、短暂的局部缺血发作、周围动脉闭塞性疾病、肺栓塞或深部静脉血栓形成。
- 一种治疗FXIa因子介导的疾病的方法,其中,包含对患有FXIa因子介导的疾病的患者施用治疗有效量的权利要求1~20任意一项所述化合物或其可药用盐或治疗有效量的权利要求22或23所述的药物组合物。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080045588.6A CN114026087B (zh) | 2019-06-28 | 2020-06-28 | 三并环类化合物及其制备方法和用途 |
KR1020227003133A KR102500570B1 (ko) | 2019-06-28 | 2020-06-28 | 삼환식 화합물, 이의 제조방법 및 용도 |
EP20831948.3A EP3998263A4 (en) | 2019-06-28 | 2020-06-28 | TRICYCLIC COMPOUND, PRODUCTION METHOD THEREOF AND USE THEREOF |
AU2020301451A AU2020301451B2 (en) | 2019-06-28 | 2020-06-28 | Tricyclic compound, preparation method therefor and use thereof |
US17/621,901 US11518766B2 (en) | 2019-06-28 | 2020-06-28 | Tricyclic compound, preparation method therefor and use thereof |
JP2021578162A JP7222123B2 (ja) | 2019-06-28 | 2020-06-28 | 三環式化合物及びその製造方法と使用 |
CA3145111A CA3145111C (en) | 2019-06-28 | 2020-06-28 | Tricyclic compound, preparation method therefor and use thereof |
BR112021026556A BR112021026556A2 (pt) | 2019-06-28 | 2020-06-28 | Composto tricíclico, método de preparação para ele e uso dele |
IL289416A IL289416B2 (en) | 2019-06-28 | 2021-12-27 | A tricyclic compound and its use |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910578620 | 2019-06-28 | ||
CN201910578620.6 | 2019-06-28 | ||
CN202010129623 | 2020-02-28 | ||
CN202010129623.4 | 2020-02-28 | ||
CN202010561350.0 | 2020-06-18 | ||
CN202010561350 | 2020-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020259668A1 true WO2020259668A1 (zh) | 2020-12-30 |
Family
ID=74060758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/098412 WO2020259668A1 (zh) | 2019-06-28 | 2020-06-28 | 三并环类化合物及其制备方法和用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11518766B2 (zh) |
EP (1) | EP3998263A4 (zh) |
JP (1) | JP7222123B2 (zh) |
KR (1) | KR102500570B1 (zh) |
CN (1) | CN114026087B (zh) |
AU (1) | AU2020301451B2 (zh) |
BR (1) | BR112021026556A2 (zh) |
CA (1) | CA3145111C (zh) |
IL (1) | IL289416B2 (zh) |
TW (1) | TW202115057A (zh) |
WO (1) | WO2020259668A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022013417A1 (en) * | 2020-07-17 | 2022-01-20 | Syngenta Crop Protection Ag | Pesticidally active heterocyclic derivatives with sulfur containing substituents |
WO2023002984A1 (ja) * | 2021-07-20 | 2023-01-26 | 小野薬品工業株式会社 | イミダゾール化合物の製造方法 |
WO2023179624A1 (zh) * | 2022-03-21 | 2023-09-28 | 上海济煜医药科技有限公司 | 三并环类化合物制备方法及其中间体 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013118805A1 (ja) * | 2012-02-08 | 2013-08-15 | 大日本住友製薬株式会社 | 3位置換プロリン誘導体 |
CN105228996A (zh) * | 2013-03-25 | 2016-01-06 | 百时美施贵宝公司 | 作为因子XIa抑制剂的含取代唑类的四氢异喹啉 |
JP2017218449A (ja) * | 2016-06-06 | 2017-12-14 | 小野薬品工業株式会社 | ジヒドロインドリジノン誘導体を含有する医薬組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014CN04676A (zh) | 2011-12-21 | 2015-09-18 | Ono Pharmaceutical Co | |
GB2497806A (en) * | 2011-12-21 | 2013-06-26 | Ono Pharmaceutical Co | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
ES2814098T3 (es) * | 2014-12-10 | 2021-03-26 | Ono Pharmaceutical Co | Derivado de dihidroindolizinona |
EP3283464B1 (en) * | 2015-04-16 | 2019-10-23 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
-
2020
- 2020-06-28 EP EP20831948.3A patent/EP3998263A4/en active Pending
- 2020-06-28 AU AU2020301451A patent/AU2020301451B2/en active Active
- 2020-06-28 BR BR112021026556A patent/BR112021026556A2/pt unknown
- 2020-06-28 CA CA3145111A patent/CA3145111C/en active Active
- 2020-06-28 JP JP2021578162A patent/JP7222123B2/ja active Active
- 2020-06-28 CN CN202080045588.6A patent/CN114026087B/zh active Active
- 2020-06-28 WO PCT/CN2020/098412 patent/WO2020259668A1/zh unknown
- 2020-06-28 US US17/621,901 patent/US11518766B2/en active Active
- 2020-06-28 KR KR1020227003133A patent/KR102500570B1/ko active IP Right Grant
- 2020-06-29 TW TW109121879A patent/TW202115057A/zh unknown
-
2021
- 2021-12-27 IL IL289416A patent/IL289416B2/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013118805A1 (ja) * | 2012-02-08 | 2013-08-15 | 大日本住友製薬株式会社 | 3位置換プロリン誘導体 |
CN105228996A (zh) * | 2013-03-25 | 2016-01-06 | 百时美施贵宝公司 | 作为因子XIa抑制剂的含取代唑类的四氢异喹啉 |
JP2017218449A (ja) * | 2016-06-06 | 2017-12-14 | 小野薬品工業株式会社 | ジヒドロインドリジノン誘導体を含有する医薬組成物 |
Non-Patent Citations (2)
Title |
---|
AVERY CRAIG A; PEASE RICHARD J; SMITH KERRIE; BOOTHBY MAY; BUCKLEY HELEN M; GRANT PETER J; FISHWICK COLIN W G: "(±) cis-bisamido epoxides: A novel series of potent FXIII-A inhibitors.", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 98, 16 May 2015 (2015-05-16), pages 49 - 53, XP029163234, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2015.05.019 * |
RAMI A AL-HORANI; UMESH R DESAI: "Factor XIa inhibitors: A review of the patent literature.", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 26, no. 3, 3 March 2016 (2016-03-03), pages 323 - 345, XP055300510, ISSN: 1354-3776, DOI: 10.1517/13543776.2016.1154045 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022013417A1 (en) * | 2020-07-17 | 2022-01-20 | Syngenta Crop Protection Ag | Pesticidally active heterocyclic derivatives with sulfur containing substituents |
WO2023002984A1 (ja) * | 2021-07-20 | 2023-01-26 | 小野薬品工業株式会社 | イミダゾール化合物の製造方法 |
WO2023179624A1 (zh) * | 2022-03-21 | 2023-09-28 | 上海济煜医药科技有限公司 | 三并环类化合物制备方法及其中间体 |
TWI833610B (zh) * | 2022-03-21 | 2024-02-21 | 大陸商上海濟煜醫藥科技有限公司 | 三并環類化合物製備方法及其中間體 |
Also Published As
Publication number | Publication date |
---|---|
KR20220020395A (ko) | 2022-02-18 |
JP2022530718A (ja) | 2022-06-30 |
IL289416A (en) | 2022-02-01 |
AU2020301451A1 (en) | 2022-02-24 |
US11518766B2 (en) | 2022-12-06 |
IL289416B2 (en) | 2023-04-01 |
CA3145111A1 (en) | 2020-12-30 |
CN114026087A (zh) | 2022-02-08 |
CN114026087B (zh) | 2023-07-18 |
EP3998263A1 (en) | 2022-05-18 |
TW202115057A (zh) | 2021-04-16 |
EP3998263A4 (en) | 2023-09-06 |
JP7222123B2 (ja) | 2023-02-14 |
KR102500570B1 (ko) | 2023-02-16 |
AU2020301451B2 (en) | 2023-02-16 |
US20220251095A1 (en) | 2022-08-11 |
IL289416B (en) | 2022-12-01 |
BR112021026556A2 (pt) | 2022-02-15 |
CA3145111C (en) | 2023-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102500570B1 (ko) | 삼환식 화합물, 이의 제조방법 및 용도 | |
KR101866706B1 (ko) | 1-알킬-6-옥소-1,6-디하이드로피리딘-3-일 화합물과 sgrm 조절인자로서의 용도 | |
JP7187575B2 (ja) | Rhoキナーゼ阻害剤としてのベンゾピラゾール系化合物 | |
TW201412737A (zh) | 吡唑並[3,4-c]吡啶類衍生物、其製備方法及其在醫藥上的應用 | |
WO2020233641A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
CA3106385A1 (en) | Imidazopyridinone compound | |
JP2010505836A (ja) | ヒンバシンの修飾された三環単位に基づいたトロンビン受容体アンタゴニスト | |
WO2016011940A1 (zh) | 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用 | |
KR20210097161A (ko) | 헤모글로빈 조절제로서의 피라졸 | |
JP7102388B2 (ja) | 単環式ヘテロアリール置換化合物 | |
JP2022522701A (ja) | ベンゾインダゾロン化合物およびその製造中間体 | |
WO2021110076A1 (zh) | 草酰胺类衍生物、其制备方法及其在医药上的应用 | |
CN113135929A (zh) | 呋喃并吡啶酮酰胺化合物及其制备方法和用途 | |
CN112778273B (zh) | 环酮并吡啶酮类化合物及其制备方法和用途 | |
CN112341377A (zh) | 一种杂环类化合物及其应用 | |
CN113135930A (zh) | 呋喃并吡啶酮咪唑化合物及其制备方法和用途 | |
TW202328076A (zh) | Sos1抑制劑及其用途 | |
JP2023538067A (ja) | イミダゾキノリンまたはベンゾインダゾロン化合物およびその製造中間体 | |
CN112778277A (zh) | 环酮并吡啶酮联杂芳环化合物及其制备方法和用途 | |
WO2019011166A1 (zh) | 大环酰胺化合物及其药物组合物和用途 | |
CN110343089A (zh) | 苯并咪唑类衍生物及其药学用途 | |
WO2015081901A1 (zh) | 取代的4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20831948 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3145111 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021578162 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021026556 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227003133 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112021026556 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211227 |
|
ENP | Entry into the national phase |
Ref document number: 2020831948 Country of ref document: EP Effective date: 20220128 |
|
ENP | Entry into the national phase |
Ref document number: 2020301451 Country of ref document: AU Date of ref document: 20200628 Kind code of ref document: A |